Literature DB >> 7151847

Disposition of pulse dose methylprednisolone in adult and paediatric patients with the nephrotic syndrome.

B M Assael, G Banfi, A C Appiani, A Edefonti, W J Jusko.   

Abstract

The disposition of a large pulse-dose of methylprednisolone was examined in paediatric and adult patients with the nephrotic syndrome. Plasma concentrations and urinary excretion rates were measured by high performance liquid chromatography. Most of the dose was metabolized, as indicated by urinary recovery of less than 10 percent of the dose. There was only slight age-dependence of the plasma clearance and volume of distribution of the steroid, although the T1/2 and mean transit time were shorter in younger patients. The pharmacokinetic parameters of the large doses (12-20 mg/kg) were similar to low dose (0.5-1 mg/kg) data from asthmatic patients. The limited variability of the pharmacokinetics of methylprednisolone suggests that tissue sensitivity may be a more important indicator of drug dosage needs in nephrotic syndrome.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7151847     DOI: 10.1007/bf00605993

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  A comparative study of the metabolism of hydrocortisone and prednisolone.

Authors:  C A NUGENT; K EIK-NES; F H TYLER
Journal:  J Clin Endocrinol Metab       Date:  1959-05       Impact factor: 5.958

2.  Pharmacokinetics of drugs in patients with the nephrotic syndrome.

Authors:  R Gugler; D W Shoeman; D H Huffman; J B Cohlmia; D L Azarnoff
Journal:  J Clin Invest       Date:  1975-06       Impact factor: 14.808

3.  Controlled trial of azathioprine in children with nephrotic syndrome. A report for the international study of kidney disease in children.

Authors:  M Abramowicz; H L Barnett; C M Edelmann; I Greifer; O Kobayashi; G C Arneil; B A Barron; G Gordillo-P; N Hallman; H A Tiddens
Journal:  Lancet       Date:  1970-05-09       Impact factor: 79.321

4.  The effects of massive doses of methylprednisolone on myocardial contractility and peripheral vascular resistance.

Authors:  P L Tecklenberg; E M Mullin; E B Stinson; A G Morrow
Journal:  Am Heart J       Date:  1973-02       Impact factor: 4.749

5.  Animal scale-up.

Authors:  R L Dedrick
Journal:  J Pharmacokinet Biopharm       Date:  1973-10

6.  Corticosteroid analysis in biological fluids by high-performance liquid chromatography.

Authors:  J Q Rose; W J Jusko
Journal:  J Chromatogr       Date:  1979-03-01

7.  The big shot.

Authors: 
Journal:  Lancet       Date:  1977-03-19       Impact factor: 79.321

Review 8.  Monitoring prednisone and prednisolone.

Authors:  W J Jusko; J Q Rose
Journal:  Ther Drug Monit       Date:  1980       Impact factor: 3.681

9.  The effect of troleandomycin on methylprednisolone elimination.

Authors:  S J Szefler; J Q Rose; E F Ellis; S L Spector; A W Green; W J Jusko
Journal:  J Allergy Clin Immunol       Date:  1980-12       Impact factor: 10.793

10.  Prednisolone disposition in steroid-dependent asthmatic children.

Authors:  J Q Rose; J A Nickelsen; E F Ellis; E Middleton; W J Jusko
Journal:  J Allergy Clin Immunol       Date:  1981-03       Impact factor: 10.793

View more
  6 in total

1.  Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers.

Authors:  E Perucca; A Albrici; G Gatti; R Spalluto; M Visconti; A Crema
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jul-Sep       Impact factor: 2.441

Review 2.  Current treatment recommendations for lupus nephritis.

Authors:  C Ponticelli
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

Review 3.  Pharmacokinetic considerations in the treatment of inflammatory bowel disease.

Authors:  M Schwab; U Klotz
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  High-dose methylprednisolone sodium succinate (pulse therapy) in the treatment of renal disease: plasma and urine concentrations.

Authors:  M Searle; G Lawson; J Chakraborty; E M Baylis; H A Lee; V Marks
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults.

Authors:  S J Szefler; W F Ebling; J W Georgitis; W J Jusko
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

6.  Methylprednisolone pharmacokinetics after intravenous and oral administration.

Authors:  S M Al-Habet; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.